A Trial Assessing the Implications of Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN: SIMPLIFY).
Phase of Trial: Phase III
Latest Information Update: 19 Dec 2013
At a glance
- Drugs Insulin degludec (Primary) ; Antihyperglycaemics; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms BEGIN; BEGIN-SIMPLIFY
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 17 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Jul 2010 Planned end date changed from 1 Dec 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.